Nkarta, Inc. (NKTX) Form 10-Q — Aug 10, 2026
Nkarta reported a second-quarter 2026 net loss of $40.4 million, or $0.54 per share, nearly double the $23.0 million loss a year earlier, as R&D spending rose to $29.0 million on higher NKX019 clinical, manufacturing and materials costs for its autoimmune disease trials. The first-half net loss reached $68.2 million versus $55.0 million in the prior-year period. The company recorded $8.0 million of impairment charges in June 2026 covering equipment it no longer plans to use and a right-of-use asset tied to plans to sublease part of its South San Francisco facility, reflecting ongoing optimization of its manufacturing operations.
Key figures
- Eps
- -$0.54 (Q2 2026 basic and diluted; -$0.92 for H1 2026)
- Net Income
- -$40.4 million (Q2 2026 net loss)
- Total Assets
- $337.6 million (June 30, 2026)
- Cash Position
- $243.2 million (cash, cash equivalents, restricted cash and investments as of June 30, 2026)
- Shares Outstanding
- 71624791
- Atm program
- $100.0 million with Stifel as sales agent; no sales as of June 30, 2026
- Cash runway
- at least 12 months from the filing date per management
- H1 2026 net loss
- $68.2 million vs $55.0 million in H1 2025
- Q2 2026 net loss
- $40.4 million vs $23.0 million in Q2 2025
- Q2 2026 ga expense
- $14.1 million vs $6.4 million in Q2 2025
- Q2 2026 rd expense
- $29.0 million vs $20.8 million in Q2 2025
- Accumulated deficit
- $716.5 million as of June 30, 2026
- Stockholders equity
- $247.7 million as of June 30, 2026 (down from $312.3 million at year-end 2025)
- Impairment charges q2 2026
- $8.0 million total ($5.7 million property and equipment; $2.4 million right-of-use asset)
- Shelf registration capacity
- $350.0 million (S-3 effective April 3, 2026)
- Net cash used in operating h1 2026
- $52.4 million
Price after filing
Close on the filing date to close N calendar days later (from $2.41). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.